Marvell Technology Group Ltd (MRVL)vsSanofi ADR (SNY)
MRVL
Marvell Technology Group Ltd
$316.43
-0.36%
TECHNOLOGY · Cap: $264.11B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $102.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 443% more annual revenue ($47.35B vs $8.72B). MRVL leads profitability with a 29.0% profit margin vs 16.0%. MRVL appears more attractively valued with a PEG of 1.64. MRVL earns a higher WallStSmart Score of 55/100 (C).
MRVL
Buy55
out of 100
Grade: C
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MRVL.
Margin of Safety
+5.6%
Fair Value
$49.84
Current Price
$44.38
$5.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Keeps 29 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Revenue surging 27.6% year-over-year
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 18.7x book value
Grey zone — moderate risk
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRVL
The strongest argument for MRVL centers on Market Cap, Profit Margin, Debt/Equity. Profitability is solid with margins at 29.0% and operating margin at 14.5%. Revenue growth of 27.6% demonstrates continued momentum.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : MRVL
The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 104.0x leaves little room for execution misses.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MRVL profiles as a growth stock while SNY is a mature play — different risk/reward profiles.
MRVL carries more volatility with a beta of 2.25 — expect wider price swings.
MRVL is growing revenue faster at 27.6% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
MRVL scores higher overall (55/100 vs 51/100), backed by strong 29.0% margins and 27.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Marvell Technology Group Ltd
TECHNOLOGY · SEMICONDUCTORS · USA
Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other SEMICONDUCTORS Stocks
Want to dig deeper into these stocks?